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INTRODUCTION
The combination of high-dose chemoradiotherapy and
allogeneic blood or bone marrow transplantation (BMT)
can cure a variety of hematologic malignancies but is not an
option for many patients who lack an HLA-matched donor,
either related or unrelated. Although there is a greater than
95% chance that any patient has a living partially HLA-
mismatched, or “haploidentical,” first-degree relative [1],
2 or 3 HLA antigen–mismatched BMT has been compli-
cated by high rates of fatal graft rejection, signiﬁcant graft-
versus-host disease (GVHD), and transplantation-related
mortality [2-8]. Thus, development of a tolerable approach
to HLA-haploidentical BMT that limits graft rejection and
GVHD is an important goal, because the graft-versus-
leukemia effect may be augmented in this setting [2,4].
A major goal of nonmyeloablative stem cell transplantation
is to minimize conditioning-regimen toxicity. Moreover, the
use of nonmyeloablative conditioning for HLA-mismatched
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ABSTRACT
Cyclophosphamide (Cy) is a potent immunosuppressive agent that is selectively toxic to lymphocytes proliferating in
response to recent antigen stimulation. In animal models, both graft rejection and GVHD after histoincompatible
BMT can be inhibited by the posttransplantation administration of high-dose Cy. Therefore, a phase I clinical trial was
undertaken to determine the minimal conditioning, including posttransplantation Cy, that permits the stable engraft-
ment of partially HLA-mismatched marrow (up to 3 HLA antigens) from first-degree relatives. Thirteen patients
(median age, 53 years) with high-risk hematologic malignancies received conditioning with fludarabine, 30 mg/m2 per
day from days –6 to –2, and TBI, 2 Gy on day –1. All patients received Cy, 50 mg/kg on day 3, mycophenolate mofetil
from day 4 to day 35, and tacrolimus from day 4 to day ≥50. Three patients in cohort 1 received no additional condi-
tioning, and 2 experienced graft rejection. Ten patients in cohort 2 received identical conditioning with the addition of
Cy 14.5 mg/kg on days –6 and –5. Sustained donor cell engraftment occurred in 8 of these patients, with a median time
to absolute neutrophil count >500/µL of 15 days (range, 13-16 days) and to unsupported platelet count >20,000/µL of
14 days (range, 0-26 days). All patients with engraftment achieved ≥95% donor chimerism within 60 days of transplan-
tation. Two patients with myelodysplastic syndrome rejected their grafts but experienced autologous neutrophil recov-
ery at 24 and 44 days. Histologic acute GVHD developed in 6 patients (grade II in 3 patients, grade III in 3 patients) at
a median of 99 days (range, 38-143 days) after transplantation and was fatal in 1 patient. At a median follow-up of
191 days (range, 124-423 days), 6 of 10 patients in cohort 2 were alive, and 5 were in complete remission of their dis-
ease, including both patients with graft rejection. These data demonstrate that partially HLA-mismatched bone mar-
row can engraft rapidly and stably after nonmyeloablative conditioning that includes posttransplantation Cy. Clinically
significant antitumor responses occur, even among patients who reject their donor grafts.
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BMT would carry the additional safeguard of recovery of
autologous hematopoiesis in the event of graft rejection. For
example, Storb and colleagues have found that posttrans-
plantation administration of cyclosporine A (CsA) and
mycophenolate mofetil (MMF) permits engraftment of
major histocompatibility complex (MHC)-identical allo-
geneic bone marrow in dogs conditioned with only 200 cGy
total body irradiation (TBI) [9]. When this strategy was
applied to patients receiving HLA-identical sibling periph-
eral blood grafts, a 20% incidence of nonfatal graft rejection
was observed [10]. However, the incidence of graft rejection
in this setting was reduced to 3% when a 3-day course of
pretransplantation ﬂudarabine was added to low-dose TBI
and posttransplantation CsA and MMF [11]. However, non-
myeloablative conditioning is unlikely to be sufficient for
preventing rejection of HLA-mismatched allogeneic trans-
plants. Ildstad and colleagues found that posttransplantation
high-dose cyclophosphamide (Cy) permitted engraftment of
MHC-incompatible marrow grafts after nonmyeloablative
conditioning in mice [12,13]. Owens and Santos had found
earlier that posttransplantation high-dose Cy also effectively
prevented GVHD in mice [14]. Because of its potent
immunosuppressive properties, Cy has been the backbone of
most pretransplantation high-dose conditioning regimens
for allogeneic BMT [15-17], but concerns about its myelo-
toxicity have deterred clinical application of high-dose Cy in
the posttransplantation setting. However, it is now clear that
high-dose Cy does not induce myeloablation; full autolo-
gous hematopoietic recovery occurs rapidly when transplan-
tation doses of Cy are used alone as treatment for autoimmune
disorders [18]. The unique pharmacology of high-dose Cy
is responsible for its ability to induce maximal immuno-
suppression without myeloablation. Hematopoietic stem
cells express high levels of aldehyde dehydrogenase, an
enzyme responsible for cellular resistance to Cy, whereas
B-lymphocytes, T-lymphocytes, and natural killer (NK)
cells express low levels of the enzyme and are extremely sen-
sitive to the cytotoxic properties of Cy [19]. The use of high-
dose Cy early after BMT, during activation of alloreactive
effector cells, may accentuate its cytotoxic activity against
both host-versus-graft (HVG) and GVH reactions [20,21].
With this background, we have developed a nonmye-
loablative conditioning regimen that uses pretransplanta-
tion fludarabine and 200 cGy TBI, with high-dose Cy
administered on day 3 after BMT [22]. This regimen per-
mitted stable engraftment of major +/– minor histocompat-
ibility antigen–mismatched marrow, including 3 MHC
antigen–mismatched haploidentical marrow, in the vast
majority of donor-recipient pairs of mice. In addition to
preventing graft rejection, high-dose posttransplantation
Cy ameliorated GVHD after MHC-mismatched BMT in
mice receiving either myeloablative or nonmyeloablative
conditioning. Addition of pretransplantation Cy to the con-
ditioning regimen was also found to increase immunosup-
pression and augmented donor chimerism, as recently
described by Petrus et al. [23]. Based on these data, we ini-
tiated a clinical trial in patients with high-risk hematologic
malignancies undergoing nonmyeloablative BMT from
HLA-haploidentical donors to determine the effective dose
of pretransplantation Cy required for full donor engraft-
ment. To reduce the risk of GVHD, all patients received
posttransplantation immunosuppression with high-dose Cy
on day 3 plus the potent combination of MMF and
tacrolimus [10,24]. Because calcineurin inhibitors, such as
CsA or tacrolimus, inhibit Cy-induced immunologic toler-
ance [25], treatment with tacrolimus and MMF was delayed
until day 4 after BMT.
PATIENTS AND METHODS
Patients
Eligible patients were 0.5 to 70 years of age with high-
risk hematologic malignancies for whom standard allogeneic
BMT (HLA-matched, related or unrelated) or autologous
BMT were unavailable or inappropriate. Eligible diagnoses
included interferon-refractory chronic myeloid leukemia
(CML) in first chronic phase, CML in second chronic
phase, poor-risk acute leukemia in ﬁrst complete remission,
acute leukemia in second or subsequent remission, myelo-
dysplastic syndrome (MDS), and chemotherapy-resistant
lymphoma or multiple myeloma. Patients had an Eastern
Cooperative Oncology Group (ECOG) performance status
of 0 or 1. Criteria for organ function were forced expiratory
volume (FEV1) ≥40% predicted, left ventricular ejection frac-
tion ≥35%, and total bilirubin ≤3.0 mg/dL. Informed con-
sent was obtained from patients using forms approved by
the Joint Committee on Clinical Investigation of the Johns
Hopkins University.
HLA Typing
HLA class I typing was performed by microcytotoxicity
using a combination of locally procured and commercially
obtained typing sera for patients and donors enrolled prior
to July 1, 2000. Subsequently, all class I typing was per-
formed by sequence-specific primer amplification (SSP)
using commercial primers (Pel-Freez Clinical System,
Brown Deer, WI) to deﬁne intermediate-resolution HLA-A,
B, and Cw allele groups. In 3 cases, sufﬁcient family mem-
bers were available for genotyping and only low-resolution
typing for DRB1 was done by SSP (One Lambda, Canoga
Park, CA). In all other cases, DRB1 alleles were deﬁned by
reverse sequence-specific oligonucleotide probe (SSOP)
hybridization (LiPA, Innogenetics, Gent, Belgium) or by
automated cycle sequencing using dye terminator chemistry
analyzed on an ABI 377PRISM DNA sequencer (Applied
Biosystems, Foster City, CA). DQB1 alleles were typed to
intermediate resolution by reverse SSOP. All molecular typ-
ing was done from genomic DNA samples extracted from
peripheral blood lymphocytes (QIAamp blood kit, Qiagen,
Chatsworth, CA).
Trial Design 
The major objective of the clinical trial was to deter-
mine the minimum dose of pretransplantation Cy for pre-
vention of allograft rejection. The dose of Cy was titrated
according to a modified method of continual reassessment
[26]. The first cohort of 3 patients received no pretrans-
plantation Cy. In the absence of efficacy, defined as graft
rejection in 2 of the first 2 or 3 patients, the dose of pre-
transplantation Cy was escalated. Ten patients in the sec-
ond treatment cohort received Cy 14.5 mg/kg per day on
days –6 and –5.
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Transplantation Regimen 
Patients received conditioning therapy with ﬂudarabine
30 mg/m2 per day intravenously (IV) on days –6 to –2 [27]
followed by 200 cGy of TBI on day –1 [9,12,13,28] (Figure 1).
The patients then received a marrow allograft (depleted of
red blood cells and plasma by processing on a Gambro Spec-
tra apheresis instrument) on day 0. On day 3, 50 mg/kg Cy
was administered over 90 minutes together with Mesna (80%
dose of Cy in 4 divided doses over 8 hours) by IV infusion.
The ﬁrst 9 patients (3 patients in cohort 1 and 6 patients in
cohort 2) received MMF (Cellcept; Roche Laboratories,
Nutley, NJ) 15 mg/kg orally twice a day from days 4 to 35
and tacrolimus (Prograf; Fujisawa, Deerﬁeld, IL) from days 4
to 50. Tacrolimus was initiated at a dose of 1 mg IV daily,
adjusted to achieve a therapeutic level of 5 to 15 ng/mL, and
then converted to oral form until discontinuation. Because
GVHD developed after day 100 in 3 of the ﬁrst 6 patients of
cohort 2, a decision was made to extend tacrolimus treatment
in all patients with ≥95% donor chimerism at day 60. Patients
received filgrastim (Neupogen; Amgen, Thousand Oaks,
CA), 5 µg/kg per day by subcutaneous injection starting on
day 1 and continuing until the recovery of neutrophils to
>1000/µL for 3 days. Prophylactic antimicrobial therapy was
started on day –6 and included norfloxacin 400 mg orally
twice daily, ﬂuconazole 400 mg orally daily, appropriate pro-
phylaxis for Pneumocystis carinii pneumonia, and valacyclovir
500 mg orally thrice daily, as described previously [29].
Cytomegalovirus (CMV) antigenemia was monitored weekly
if recipients and/or donors were seropositive. If patients were
found to be antigenemic, preemptive treatment with ganci-
clovir, 5 mg/kg IV twice daily, was initiated for 14 days and
then continued daily until CMV antigenemia test results were
negative for at least 2 weeks. All treatment was performed on
an outpatient basis unless otherwise speciﬁed.
Engraftment and Donor Chimerism
Neutrophil recovery was defined as an absolute neu-
trophil count (ANC) greater than 500/µL, and platelet
recovery was defined as a platelet count greater than
20,000/µL for 7 days without transfusion. Donor chimerism
was determined either by restriction fragment length poly-
morphisms [30], polymerase chain reaction analysis of vari-
able nucleotide tandem repeats [31,32], or fluorescence in
situ hybridization (FISH) [33] using X- and Y-chromosome
probes, if informative. In patient 3267, XY-FISH was per-
formed on peripheral blood mononuclear cells after cellular
subsets were fractionated on a MACS separation device
(Miltenyi Biotech, Auburn, CA) using appropriate monoclo-
nal antibodies conjugated to immunomagnetic beads. Date
of last patient follow-up was April 9, 2002.
Immune Reconstitution
Peripheral blood lymphocyte subsets were quantiﬁed by
flow cytometry using monoclonal antibodies to T-cells
(CD3, -4, -8) or NK cells (CD56). Measurements were
made at baseline, prior to administration of the conditioning
regimen, and weekly after neutrophil counts had recovered
to >1000/µL after BMT.
Therapy of GVHD
Acute GVHD was graded according to the Keystone
criteria [34]. Treatment approaches are described in the text.
Agents used to treat GVHD in addition to methylpred-
nisolone included inﬂiximab (Remicade; Centocor, Malvern,
PA), daclizumab (Zenapax; Hoffman-La Roche, Nutley, NJ),
and 2-deoxycoformycin (pentostatin, Nipent; SuperGen,
San Ramon, CA).
RESULTS
Patient and Donor Characteristics 
Table 1 describes the 3 patients in cohort 1 (no Cy
before BMT) and the 10 patients in cohort 2 (Cy 14.5 mg/kg
each on days –6 and –5). All patients had poor-risk hemato-
logic malignancies and no option of autologous or HLA-
identical allogeneic BMT. Median age of recipients was
53 years (range, 23-63 years). HLA typing of the patients
and their donors is shown in Table 2. Donors (median age,
37 years; range, 22-63 years) were siblings in 5 cases, chil-
dren in 6 cases, and parents in 2 cases. Seven donor-
recipient pairs were compatible for the ABO blood group
antigens. In 2 pairs, recipients had antibodies against donor
ABO antigens (a major ABO incompatibility), whereas in
4 pairs, donors had antibodies against recipient ABO anti-
gens (a minor ABO incompatibility). No hemolysis was
observed in any of the ABO-incompatible transplantations.
All patients had received prior therapy except for 3 patients
with MDS: patient 3303 in cohort 1 and patients 3486 and
3529 in cohort 2.
Graft Composition
Allografts consisted of 1.2 ± 0.1 × 108 mononuclear
cells/kg (mean ± 95% conﬁdence interval) containing 5.3 ±
1.5 × 106 CD34+ cells/kg and 3.2 ± 0.6 × 107 CD3+ cells/kg.
Figure 1. Treatment schema. All patients received ﬂudarabine from days –6 to –2, 200 cGy TBI on day –1, a haploidentical bone marrow infusion
on day 0, Cy on day 3, and MMF on days 4 to 35. Granulocyte colony-stimulating factor (G-CSF) treatment was discontinued when the ANC
exceeded 1000/µL for 3 consecutive days. All patients in cohort 2 received Cy on days –6 and –5; the last 2 patients of this cohort received
tacrolimus beyond day 100.
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Table 1. Patient Characteristics*
Cohort UPIN Age Sex Diagnosis
1 3267 56 F Secondary AML (MDS) in CR1 following induction chemotherapy
3298 40 M Ph+ ALL in CR1 following induction and consolidation chemotherapy
3303 63 F Hypoplastic MDS; no prior chemotherapy; transfusion-dependent for 10 mo
2 1706 49 M Stage IV diffuse mixed small cleaved and large cell lymphoma in CR following chemotherapy; relapse 
after 1 y; CR following chemotherapy, autologous BMT; recurrent abdominal mass, bone lesion 
after 5 y; CR following radiochemotherapy; recurrence with pathologic fracture of left femoral 
neck after 3 y; PR following chemotherapy, anti-CD20 therapy 
3384 41 M CML-CP on interferon therapy; progression to blast crisis after 4 y; CP2 following induction 
chemotherapy
3391 53 F Ph+ ALL in CR1 following induction and consolidation chemotherapy
3434 60 M Primary refractory Stage II multiple myeloma following chemotherapy and high-dose dexamethasone
3271 23 F M5-AML in CR1 following induction chemotherapy; consolidation by purged autologous BMT; 
relapse after 6 mo, CR2 following anti-CD33 therapy
3446 57 F M1-AML in CR1 following induction and consolidation chemotherapy; relapse after 3 mo; CR2 
following anti-CD33 therapy
3486 38 M RAEB × 2 y with slow progression to AML; transfusion-dependent × 2 y; no prior therapy
3529 61 M Hypoplastic MDS/AA progressing to AML at 19 mo; no prior therapy; red cell and platelet 
transfusion-dependent
3545 48 F CML × 20 mo; interferon × 15 mo without cytogenetic response; MDS, no prior therapy
3563 53 F Secondary AML (MDS) in early relapse (by flow cytometry) after induction chemotherapy
*CR indicates complete remission; PR, partial remission; CP, chronic phase; RAEB, refractory anemia with excess blasts; AA, aplastic anemia.
Table 2. HLA Typing
Degree and Direction of HLA Mismatch†
Mismatched HLA Haplotype* 3-Locus Mismatch 5-Locus Mismatch 
Patient Donor Age Class I Antigens‡ Class II Alleles§ A;B;DRB1 A;B;C;DRB1;DQB1
UPIN Age/Sex (Relationship) A B C DRB1 DQB1 HVG GVH HVG GVH
3267 56/F 25 (Son) 11 51 4 04011 0301 2 (A,B) 4 (A,B,C, DQ)
26 49 7 [01xx] 0504 3 5
3298 40/M 34 (Brother) 26 27 2 15011 06WG 3 4 (A,B,DR,DQ)
29 60 [7] 1302 06DE 3 5
3303 63/F 38 (Daughter) 24 [7] [7] [15011] [06WG] 3 4 (A,B,DR,DQ)
32 71 [7] 04011 03TF 1 (A) 1 (A)
1706 49/M 25 (Son) 11 35 4 03011 02AB 1 (B) 1 (B)
11 8 [7] 03011 02AB 1 (B) 2 (B,C)
3384 41/M 37 (Sister) 1 7 7 15011 06xx 1 (A) 1 (A)
32 7 7 15011 06xx 1 (A) 1 (A)
3391 53/F 21 (Daughter) 33 50 6 11012 0301 3 4 (A,B,DR,DQ)
29 58 [7] 0701 02AB 3 5
3434 60/M 22 (Daughter) 1 58 3 08041 03HGB 2 (A,DR) 3 (A,C,DR)
3 58 6 1102 03HGB 2 (A,DR) 3 (A,C,DR)
3271 23/F 55 (Father) 2 35 4 [04011] 03GBP 3 5
29 44 16 07xx 02MN 2 (A,B) 4 (A,B,C,DQ)
3446 57/F 55 (Brother) 1 8 7 13011 [06xx] 1 (DR) 2 (DR,DQ)
1 8 7 03011 02MN 1 (DR) 1 (DR)
3486 38/M 55 (Mother) 2 70 3 09012 02AB 2 (A,B) 4 (A,B,C,DQ)
11 15 4 [0701] 02MN 3 5
3529 61/M 63 (Brother) 2 39 7 0801 04AB 3 5
68 53 4 13021 06xx 3 5
3545 48/F 45 (Sister) 1 8 7 03011 02MN 2 (B,DR) 4 (B,C, DR,DQ)
[2] 71 7 15011 06xx 3 5
3563 53/F 28 (Daughter) 80 45 16 01xx 05RV 3 4 (A,B,C,DR)
2 35 4 15xx 05RV 3 4 (A,B,C,DR)
*The mismatched haplotype for the patient is given on the top row and for the donor on the bottom row. Antigens or alleles in either the patient
or donor that are homozygous, ie, present on the shared haplotype, are indicated by brackets.
†The locus (loci) of the mismatches are given in parentheses for cases involving fewer than all loci.
‡The ﬁrst 5 patients and donors were typed by serology; all others were typed by SSP. Antigen equivalents are given for those typed by SSP.
§Class II alleles were deﬁned by reverse SSOP or sequence-based typing, except for those alleles designated with “xx.” In those cases, only low-
resolution SSP typing was performed, as haplotypes were assigned from family genotyping.
DQB1 alleles were typed to intermediate resolution by reverse SSOP and are designated by the codes of the National Marrow Donor Program.
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Outcomes: Cohort 1
These 3 patients received nonmyeloablative condition-
ing without pretransplantation Cy. The ﬁrst patient (UPIN
3267), with secondary acute myeloid leukemia (AML) in
first complete remission, experienced neutrophil recovery
on day 12 (Table 3) but was found to be in hematologic
relapse of leukemia on day 30 (Figure 2). Grade II acute
GVHD of the skin and liver developed on day 60, following
discontinuation of immunosuppression, but the patient died
of progressive disease on day 104. The remaining 2 patients
did not achieve engraftment with donor cells, with 1 patient
(UPIN 3298) exhibiting autologous neutrophil recovery on
day 46 after BMT and the other (UPIN 3303) dying on day
58 of infection during aplasia. Both patients were mis-
matched with their donor grafts by 3 HLA antigens in the
HVG direction, and serum taken from UPIN 3303 prior to
transplantation was also found to contain lymphocytotoxic
antibodies against donor HLA antigens.
Table 3. Outpatient Course*
Hematopoietic No. of
Recovery† Transfusions Hospital Admissions
ANC PLT Length
Cohort UPIN >500/µL >20,000/µL RBC PLT No.‡ of Stay, d Reason for Admission
1 3267 12 20 2 1 1 25 Day 42 fever/presumptive CMV infection
3298 46 NR 15 15 2 3, 8 Day 3 neutropenic fever; day 10 fever/dehydration
3303 NR NR 21 38 2 5, 34 Day –1 neutropenic fever; day 24 fungal pneumonia
2 1706 16 22 2 1 1 4 Day 32 fever/sinusitis
3384 13 12 1 1 1 2 Day 9 neutropenic fever
3391 13 13 2 2 0
3434 15 0 8 0 1 4 Day 34 fever (drug-related)
3271 15 26 7 5 0
3446 13 21 8 9 2 3, 6 Day 3 neutropenic fever; 
3486 24 20 6 1 0 day 20 fever/swollen ankle joint
3529 44 146 14 19 1 3 Day 2 neutropenic fever
3545 14 13 2 1 1 3 Day 3 neutropenic fever
3563 15 14 3 1 2 4,8 Day 1 neutropenic fever; day 27 fever, diarrhea
*PLT indicates platelets; RBC, red blood cells; NR, no recovery.
†Days post-HSCT.
‡Up to day +60, endpoint of study.
Figure 2. Patients’ clinical courses. Diagnoses are listed to the left of each timeline. A Roman numeral above the GVHD symbol indicates maxi-
mum grade of GVHD. Numbers above day 0 are unique patient identifiers (UPIN); the numbers along the timeline are percentage donor
chimerism. Disease states: M, molecular remission or relapse; BC, blast crisis; PR, partial response; CNS, central nervous system relapse; CR, com-
plete response; C, cytogenetic remission; †, death.
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Outcomes: Cohort 2
All 10 patients in this cohort received nonmyeloablative
conditioning including pretransplantation Cy 14.5 mg/kg
per day on days –6 and –5 (Figure 1).
Donor Chimerism. Sustained donor cell engraftment
occurred in 8 of 10 patients in cohort 2 (Figure 2 and Table 4).
In all 8 patients who had donor graft acceptance, donor
chimerism was >90% on the ﬁrst measurement. Chimerism
subsequently remained >90% except in the 2 patients who
developed bone marrow and hematologic relapse of their
disease (UPIN 3384 and 3271). Failure of donor cell engraft-
ment occurred in 0 of 3 donor-recipient pairs mismatched
for 1 HLA antigen in the HVG direction, in 1 of 2 pairs mis-
matched for 2 HLA antigens, and in 1 of 5 pairs mismatched
for 3 HLA antigens. Both patients who had graft rejection
had a diagnosis of MDS, no prior chemotherapy, and a long
history of transfusion dependence (Table 1).
Hematologic Recovery. Table 3 shows the neutrophil
recovery of patients in cohort 2. All patients became neu-
tropenic following conditioning therapy, with the white
blood cell count nadir occurring at a median of day 9.
Among the 8 patients who had donor graft acceptance, the
median time to an absolute neutrophil count >500/µL was
15 days (range, 13-16 days), and the median time to platelet
count >20,000/µL was 14 days (range, 0-26 days). Neu-
trophil recovery in the 2 patients with graft rejection
occurred at days 24 and 44, and platelet recovery occurred
by day 20 and 146, respectively. Among the patients with
sustained donor cell engraftment, the median number of red
blood cell transfusions was 3 (range, 1-8), and the median
number of platelet transfusions was 1 (range, 0-9).
Hospital Admissions. As shown in Table 3, 10 patients
were hospitalized for fevers, 7 of which occurred while the
patients were neutropenic. The median number of admis-
sions was 1 (range, 0-2), with a median hospital stay of
5 days (range, 2-34 days).
Acute GVHD. GVHD developed in 6 patients at a
median of 99 days after BMT (range, 38-143 days; Figure 2
and Table 4). There were 3 cases of grade II GVHD and
3 cases of grade III GVHD. Of the 8 patients with sustained
donor cell engraftment, GVHD occurred in 2 of 3 patients
mismatched for 1 HLA antigen in the GVH direction, 2 of
3 patients mismatched for 2 HLA antigens, and both
patients mismatched for 3 HLA antigens. Five patients
responded to therapy, which included combinations of
tacrolimus, steroids, psoralen-activated ultraviolet A light
therapy, inﬂiximab, daclizumab, or 2-deoxycoformycin. One
patient died of infectious complications of GVHD.
In 3 of the patients, GVHD did not occur until day 98
or later, 48 or more days after discontinuation of immuno-
suppression. One of these patients (UPIN 3271) developed
grade III GVHD 30 days after receiving a donor leukocyte
infusion at a dose of 105 CD3+ T-cells/kg for relapsed AML
(Figure 2). Because of the delayed occurrence of GVHD,
which was the proximate cause of death in 1 patient, the
treatment protocol was modiﬁed to extend the duration of
tacrolimus treatment to more than 90 days among patients
with full donor hematopoietic chimerism at day 60. Since
this modiﬁcation was implemented, 2 patients have achieved
engraftment with donor cells; 1 patient (UPIN 3563) devel-
oped grade II skin and gastrointestinal GVHD on day 143,
which was controlled with a combination of steroids and
2-deoxycoformycin (Figure 2).
Immune Reconstitution. Table 5 shows recovery of NK
cells and CD4 cells in the 6 patients of cohort 2 who were
tested. With the exception of 2 patients, 1 of whom (UPIN
3384) was on high-dose corticosteroid therapy for acute
GVHD, CD4 counts recovered to >200 cells/µL by day 40.
NK cells recovered to pretransplantation levels by day 40 in
all but 1 patient (UPIN 3434). In contrast, B-cell reconsti-
tution was delayed (not shown). No detailed phenotypic
analysis of NK cells or T-cells was performed.
Table 4. Chimerism, GVHD, and Patient Outcomes*
Donor Chimerism, %
HLA Mismatch† Day Day Day GVHD Relapse,
Cohort UPIN Diagnosis HVG GVH ~30 ~60 ~180 Acute‡ Day Chronic Day Status, Day
1 3267 AML 2 (A,B) 2 (B,DR) 70 23 ND II (S) 52 30 Died§, 104
3298 Ph+ ALL 3 3 0 ND 320 Died, 320
3303 MDS 3 1 (A) 0 ND Died, aplasia, 58
2 1706 NHL 1 (B) 1 (B) 100 100 100 Alive, NED, 423+
3384 CML-CP2 1 (A) 1 (A) 100 100 100 III (S,G) 42 271 Died, 401
3391 Ph+ ALL 3 3 100 100 100 III (S,L) 100 Died, GVHD, 183
3434 MM 2 (A,DR) 2 (A,DR) 100 100 100 II (L) 126 Limited 111 Died, 198
3271 AML 3 2 (A,B) >95 50 ND III (G) 103 60 Died, 157
3446 AML 1 (DR) 1 (DR) 100 100 100 II (S) 38 183 Alive, in relapse 290+
3486 MDS/AML 2 (A,B) 3 0 0 0 Alive, NED 332+
3529 MDS 3 3 10 0 0 Alive, NED 277+
3545 MDS/CML 3 2 (B, DR) >95 >95 >95 Alive, Cyto CR 225+
3563 MDS/AML 3 3 >95 >95 93-99 II (S,G) Alive, NED 185+
*ND indicates not determined; S, skin; NHL, non-Hodgkin’s lymphoma; G, gastrointestinal; L. liver; MM, multiple myeloma; NED, no evi-
dence of disease.
†n = number of mismatched antigens (mismatched loci)
‡Acute GVHD was deﬁned as grades I-IV, maximum grade.
§Died in relapse unless otherwise speciﬁed.
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Patient Outcomes. With a median follow-up of survivors
of 284 days (range, 185-423 days), 6 of 10 patients are alive,
and 5 patients are disease free (Table 4). Each of these
5 patients had active disease at the time of transplantation;
therefore, each has responded to therapy. This group
includes all 3 MDS patients, 2 of whom had graft rejection
but remained in a complete remission 277 and 332 days
after transplantation. The pretransplantation and most
recent blood counts for these 3 patients are shown in Fig-
ure 3. Both of the patients who had graft rejection had a
normal male karyotype in the bone marrow prior to trans-
plantation; after transplantation, 1 patient (UPIN 3529) had
a normal male karyotype and the other (UPIN 3486) had
only nonclonal abnormalities in 9 of 30 cells analyzed. Flow
cytometry of the marrow prior to transplantation revealed
22% phenotypically abnormal myeloid blasts in UPIN 3486
and 4% abnormal myeloid blasts in UPIN 3529; at 6
months after transplantation, no abnormal myeloid blasts
were found in either of these patients. The pretransplanta-
tion marrow of the patient with MDS/CML (UPIN 3545)
contained 4 clones, demonstrating trisomy 8 (4/22 cells),
monosomy 7 (3/22 cells), both (6/22 cells), or only the
Philadelphia chromosome (7/22 cells). Six months after
transplantation, this patient’s marrow contained >95%
donor cells, a normal female karyotype, and only 1 of
6000 cells expressing a bcr/abl fusion signal by the FISH
technique (normal, <5 cells).
GVHD did not appear to have a substantial beneﬁcial
effect on long-term disease-free survival, because the under-
lying malignancy either progressed or recurred in 4 of
5 patients who survived their GVHD. Three of the relaps-
ing patients have died, and the fourth was treated with radi-
ation therapy for a chloroma of the cerebrum. One patient
died in remission from infectious complications of GVHD.
DISCUSSION
Although the combination of myeloablative condition-
ing and BMT from partially mismatched related donors has
been used to treat hematologic malignancies in patients who
lack an HLA-identical donor, this procedure carries a sub-
stantial risk of fatal graft rejection, GVHD, and serious
infection resulting from prolonged immunosuppression.
Rigorous depletion of T-cells from the donor graft reduces
the risk of GVHD but increases the risk of graft rejection
and prolongs posttransplantation immunosuppression
[35-37]. GVH-reactive T-cells can be selectively tolerized
by incubating the donor graft ex vivo with host cells in the
presence of cytotoxic T-lymphocyte–associated antigen-4/
immunoglobulin fusion protein (CTLA4-Ig), a recombinant
fusion protein that blocks T-cell costimulatory interactions
[38]. Although selective induction of tolerance in donor T-cells
would in theory preserve donor T-cell responses to
pathogens and promote faster immune reconstitution after
BMT, the procedure does not obviate the need to condition
the recipient intensively to prevent graft rejection. Thus,
methods that promote selective tolerance induction in both
host and donor T-cells, while preserving general immune
responsiveness, are clearly needed.
Cy is a potent antineoplastic drug that has been exten-
sively studied for its ability to suppress immune responses,
including allogeneic reactions. Early studies demonstrated
that Cy is most effective at suppressing MHC-incompatible
skin allograft rejection when the drug is administered 2 to
3 days after placement of the graft [39,40]. Cy was also found
to have the highest therapeutic ratio of all the cytotoxic
agents tested for the promotion of immunologic tolerance
[41]. In mouse models of MHC-identical allogeneic BMT,
Cy can induce complete bidirectional tolerance, but only if
the drug is given in a high dose, ≥150 mg/kg (300 mg/m2),
48 to 72 hours after transplantation [42]. We recently found
Table 5. Lymphocyte Reconstitution in Cohort 2
NK Cells/µL CD4+ Cells/µL
UPIN Day –6 Day 40 Day –6 Day 40
1706 274 678 845 404
3384 86 228 716 69
3391 56 50 253 261
3434 166 50 417 366
3446 92 205 326 677
3486 121 156 887 146
Figure 3. Pre- and posttransplantation blood counts from patients in cohort 2 with myelodysplasia. Pretransplantation counts were obtained on day
–6; posttransplantation counts were taken on day 225 (, UPIN 3545), day 277 (H17009, UPIN 3529), and day 332 (, UPIN 3486). Patients who had
graft rejection are depicted by ﬁlled symbols.
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that posttransplantation Cy signiﬁcantly reduces both HVG
and GVH reactions after MHC-mismatched BMT without
impairing immune responses to unrelated third-party
alloantigens [22]. The protocol of Cy-induced immunologic
tolerance takes advantage of the drug’s selective toxicity to
recently activated lymphocytes. Thus, BMT stimulates the
proliferation of both HVG- and GVH-reactive T-cells,
which are selectively eliminated by the administration of Cy
[43,44]. Although Cy, even in high doses, is not toxic to
pluripotent hematopoietic stem cells [19,45], there was
some concern that exposure of the donor graft to high-dose
Cy would cause prolonged neutropenia. However, with ﬁl-
grastim included in our protocol, this concern was not
borne out clinically. The median time to a neutrophil count
>500/µL in this study was 15 days, which compares favor-
ably to the median time to neutrophil recovery of 19 days in
a retrospective study of patients receiving HLA-identical
sibling bone marrow [46] and of 20 days among patients
receiving T-cell–depleted marrow transplants from partially
HLA-mismatched related donors [5]. These results suggest
that high-dose posttransplantation Cy can be administered
safely without substantially impairing hematologic recovery.
The major objective of this study was to determine the
minimum dose of pretransplantation Cy that is required for
the stable engraftment of partially HLA-mismatched marrow
following nonmyeloablative conditioning including post-
transplantation Cy. The risk of graft rejection following allo-
geneic BMT is inﬂuenced by a variety of factors, including
conditioning regimen intensity, the chemotherapy and
transfusion history of the recipient, donor/recipient histoin-
compatibility, donor CD34+ and T-cell dose, and posttrans-
plantation pharmacologic immunosuppression. In a mouse
model of MHC-mismatched BMT, we have found that a sin-
gle high dose (200 mg/kg) of Cy is most effective at prevent-
ing graft rejection when given after, rather than before, the
transplantation, but also that the engraftment-promoting
effects of pre- and posttransplantation Cy are additive [22].
Because our patient group was quite heterogeneous with
respect to most of these criteria, it is simply not possible to
make ﬁrm conclusions about the relative importance of pre-
versus posttransplantation Cy in preventing graft rejection.
However, a number of conclusions about the effects of con-
ditioning on transplantation outcome are possible.
First, because recovery of autologous hematopoiesis
occurred in 3 of the 4 patients who had graft rejection, the
conditioning regimens used in this study are truly nonmye-
loablative. Three of the 4 patients who experienced graft
rejection had a diagnosis of MDS, were transfusion depen-
dent, and had not received any prior chemotherapy prior to
the initiation of conditioning. In a separate study, patients
with MDS were also found to have a higher risk of rejecting
HLA-identical unrelated donor stem cells after nonmyeloab-
lative conditioning than were patients with acute leukemia,
lymphoma, or multiple myeloma [47]. It is not known
whether the increased risk of graft rejection is due to an
intrinsic immunologic abnormality associated with MDS or,
as with aplastic anemia [48] and sickle cell anemia patients
[49], due to sensitization by prior blood transfusions while
immunocompetent. With regard to the latter possibility, we
have found that conditioning with fludarabine, low-dose
TBI, and posttransplantation Cy is insufficient to prevent
graft rejection in mice that have been previously sensitized to
donor tissues (L.L., E.J.F., unpublished data).
Second, a clinical beneﬁt of nonmyeloablative BMT can
be obtained even in the absence of sustained donor cell
engraftment, as illustrated by 2 patients with MDS (UPIN
3486 and 3529) who achieved a morphologic complete remis-
sion of their disease despite marrow graft rejection. This
phenomenon has also been observed in patients with chemo-
therapy-refractory non-Hodgkin’s lymphoma who lost donor
chimerism following nonmyeloablative allogeneic stem cell
transplantation [50]. There are at least 3 possible explanations
for a therapeutic effect of nonmyeloablative allogeneic BMT
in the absence of sustained donor cell engraftment. First, the
direct cytotoxicity of ﬂudarabine, TBI, and Cy on tumor cells
may induce a remission in the absence of any immunologic anti-
tumor effects. Second, a transient graft-versus-myelodysplasia
effect, sufﬁcient to eliminate the malignant cells, may occur
before the donor graft is rejected. Finally, the BMT proce-
dure may alter the immunologic milieu into one that is favor-
able to the activation of host-derived antitumor cytotoxic
effector cells. In some rodent tumor models, Cy administra-
tion unmasks a therapeutic antitumor immune response [51]
by eliminating CD4+ T-cells with suppressor activity [52] or
by disrupting tumor stroma cell interactions [53]. Therefore,
the immunologic effects of Cy administration in the condi-
tioning regimen may not be limited to its effects on engraft-
ment and GVHD.
Finally, the time to onset of GVHD in the patients
treated here may be delayed compared to that of patients
who receive haploidentical BMT after myeloablative condi-
tioning. In one study that included 119 patients receiving
1 HLA antigen–mismatched BMT, nearly all patients who
developed acute GVHD did so by day 30 after transplanta-
tion [4], whereas none of our patients had developed
GVHD by that time. Several features of our protocol may
contribute to a delayed onset and/or lessened severity of
GVHD, including the use of reduced-dose TBI [54], post-
transplantation Cy [22], and the combined administration
of a calcineurin inhibitor (tacrolimus) and MMF for
GVHD prophylaxis [24]. Of the 6 patients with GVHD,
only 2 experienced the onset of disease while receiving
tacrolimus and MMF, and donor chimerism in both of
these patients was >95% before or shortly after disease
onset (Figure 1). Because GVHD does not develop in the
absence of full donor T-cell chimerism [55], we are now
investigating the effect on the incidence and severity of
GVHD of extending pharmacologic immunosuppression in
full donor chimeras.
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